LY 233053

• Description :

  LY 233053 is a potent and competitive NMDA-receptor antagonist with anticonvulsant and antiepileptic efficacy[1][2].

• CAS Number :

  [125546-04-5]

• UNSPSC :

  12352005

• Target :

  IGluR

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/ly-233053.html

• Solubility :

  10 mM in DMSO

• Smiles :

  OC([C@@H](NCC1)C[C@@H]1CC2=NN=NN2)=O

• Molecular Formula :

  C8H13N5O2

• Molecular Weight :

  211.22

• References & Citations :

  [1]1.K K Borowicz, et al. Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice. Epilepsia. 1996 Jul;37 (7) :618-24. |[2]K P Madden, et al. Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia. J Neurosurg. 1992 Jan;76 (1) :106-10.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  NMDA Receptor